Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seagen Debuts In EU With Tukysa Launch & Sees UK As 'Key' Future Market

Pricing And Reimbursement Talks Getting Under Way

Executive Summary

Tuomo Pätsi of US biotech firm Seagen discusses plans for the rollout of Tukysa in Europe, how it successfully used a new mechanism for approval in Great Britain, and why the UK will be a go-to market for future innovative drug filings.

You may also be interested in...



Five Phase III Data Readouts To Look Out For In Q2

Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.

Enhertu Nabs A First With UK Standalone Approval

The UK conditional approval of Daiichi Sankyo/AstraZeneca’s advanced breast cancer drug Enhertu was issued in accordance with “transitional provisions” that apply to drugs that received a positive opinion from the European Medicines Agency before the end of the Brexit transition period.

UK Vaunts 'New Era' In Drug Approvals

The UK regulator, the MHRA, has published guidance on its new integrated pathway for innovative drug approvals, which it says is intended to bring together partners including health technology assessment agencies, health care bodies and patient organizations to offer “sustained collaboration” with drug developers.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144001

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel